A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence.

Hdl Handle:
http://hdl.handle.net/10147/128777
Title:
A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence.
Authors:
Farren, Conor K; Scimeca, Michael; Wu, Ran; Malley, Stephanie O
Affiliation:
Yale University School of Medicine, Department of Psychiatry, Substance Abuse Treatment Unit, 1 Long Wharf, New Haven, CT 06419, United States. cfarren@stpatsmail.com
Citation:
A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence. 2009, 99 (1-3):317-21 Drug Alcohol Depend
Journal:
Drug and alcohol dependence
Issue Date:
1-Jan-2009
URI:
http://hdl.handle.net/10147/128777
DOI:
10.1016/j.drugalcdep.2008.06.006
PubMed ID:
18644685
Additional Links:
doi:10.1016/j.drugalcdep.2008.06.006
Abstract:
Significant preclinical evidence exists for a synergistic interaction between the opioid and the serotonin systems in determining alcohol consumption. Naltrexone, an opiate receptor antagonist, is approved for the treatment of alcohol dependence. This double-blind placebo-controlled study examined whether the efficacy of naltrexone would be augmented by concurrent treatment with sertraline, a selective serotonin receptor uptake inhibitor (SSRI).; One hundred and thirteen participants meeting DSM IV alcohol dependence criteria, who were abstinent from alcohol between 5 and 30 days, were randomly assigned to receive one of two treatments at two sites. One group received naltrexone 12.5 mg once daily for 3 days, 25 mg once daily for 4 days, and 50 mg once daily for the next 11 weeks, together with placebo sertraline. The other group received naltrexone as outlined and simultaneously received sertraline 50 mg once daily for 2 weeks, followed by 100 mg once daily for 10 weeks. Both groups received group relapse prevention psychotherapy on a weekly basis.; Compliance and attendance rates were comparable and high. The groups did not differ on the two primary outcomes, time to first drink and time to relapse to heavy drinking, or on secondary treatment outcomes. With the exception of sexual side effects which were more common in the combination group, most adverse events were similar for the two conditions.; As the doses are tested in combination with specialized behavioral therapy, this study does not provide sufficient evidence for the combined use of sertraline and naltrexone above naltrexone alone.
Item Type:
Article
Language:
en
MeSH:
Adult; Age of Onset; Alcoholism; Cognitive Therapy; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Ethnic Groups; Female; Humans; Male; Marital Status; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Patient Selection; Psychiatric Status Rating Scales; Psychotherapy; Serotonin Uptake Inhibitors; Sertraline; Treatment Outcome
ISSN:
1879-0046

Full metadata record

DC FieldValue Language
dc.contributor.authorFarren, Conor Ken
dc.contributor.authorScimeca, Michaelen
dc.contributor.authorWu, Ranen
dc.contributor.authorMalley, Stephanie Oen
dc.date.accessioned2011-04-27T14:17:54Z-
dc.date.available2011-04-27T14:17:54Z-
dc.date.issued2009-01-01-
dc.identifier.citationA double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence. 2009, 99 (1-3):317-21 Drug Alcohol Dependen
dc.identifier.issn1879-0046-
dc.identifier.pmid18644685-
dc.identifier.doi10.1016/j.drugalcdep.2008.06.006-
dc.identifier.urihttp://hdl.handle.net/10147/128777-
dc.description.abstractSignificant preclinical evidence exists for a synergistic interaction between the opioid and the serotonin systems in determining alcohol consumption. Naltrexone, an opiate receptor antagonist, is approved for the treatment of alcohol dependence. This double-blind placebo-controlled study examined whether the efficacy of naltrexone would be augmented by concurrent treatment with sertraline, a selective serotonin receptor uptake inhibitor (SSRI).-
dc.description.abstractOne hundred and thirteen participants meeting DSM IV alcohol dependence criteria, who were abstinent from alcohol between 5 and 30 days, were randomly assigned to receive one of two treatments at two sites. One group received naltrexone 12.5 mg once daily for 3 days, 25 mg once daily for 4 days, and 50 mg once daily for the next 11 weeks, together with placebo sertraline. The other group received naltrexone as outlined and simultaneously received sertraline 50 mg once daily for 2 weeks, followed by 100 mg once daily for 10 weeks. Both groups received group relapse prevention psychotherapy on a weekly basis.-
dc.description.abstractCompliance and attendance rates were comparable and high. The groups did not differ on the two primary outcomes, time to first drink and time to relapse to heavy drinking, or on secondary treatment outcomes. With the exception of sexual side effects which were more common in the combination group, most adverse events were similar for the two conditions.-
dc.description.abstractAs the doses are tested in combination with specialized behavioral therapy, this study does not provide sufficient evidence for the combined use of sertraline and naltrexone above naltrexone alone.-
dc.language.isoenen
dc.relation.urldoi:10.1016/j.drugalcdep.2008.06.006en
dc.subject.meshAdult-
dc.subject.meshAge of Onset-
dc.subject.meshAlcoholism-
dc.subject.meshCognitive Therapy-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshDouble-Blind Method-
dc.subject.meshDrug Therapy, Combination-
dc.subject.meshEthnic Groups-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMarital Status-
dc.subject.meshMiddle Aged-
dc.subject.meshNaltrexone-
dc.subject.meshNarcotic Antagonists-
dc.subject.meshPatient Compliance-
dc.subject.meshPatient Selection-
dc.subject.meshPsychiatric Status Rating Scales-
dc.subject.meshPsychotherapy-
dc.subject.meshSerotonin Uptake Inhibitors-
dc.subject.meshSertraline-
dc.subject.meshTreatment Outcome-
dc.titleA double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence.en
dc.typeArticleen
dc.contributor.departmentYale University School of Medicine, Department of Psychiatry, Substance Abuse Treatment Unit, 1 Long Wharf, New Haven, CT 06419, United States. cfarren@stpatsmail.comen
dc.identifier.journalDrug and alcohol dependenceen
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.